We’ll be conducting routine maintenance on Saturday, August 3rd.
Our phone system will be unavailable during this time, but you’ll be able to chat with our live agents 24/7 or you can email Support.

The GLP-1 Forecast for 2024: Six Key Predictions

  • White Paper
  • Obesity care and GLP-1s

Summary

According to leading indicators, consumer interest in GLP-1s shows no signs of abating in 2024. Strong demand will continue to spark innovation—as evidenced by the dozens of new formulations in the pipeline—yet cost and access will remain significant obstacles for employers and employees alike.

While GLP-1 medicines can be game changers in the management of obesity, we anticipate that they will also trigger a huge wave of cost increases for employers, payors, and our entire health system.  

This white paper identifies six GLP-1 trends for the upcoming year and corresponding takeaways for employers looking to craft a proactive utilization and care management approach. 

Key recommendations for employers include:

  • Find programs anchored to behavior and lifestyle change to help employees maintain weight loss and reduce long-term medication dependency
  • Offer workforces a full-spectrum approach from prevention to clinical treatment
  • Identify partners who invest in long-term studies to test the efficacy of their care models

Download the free white paper to learn more.

Download the White Paper

By submitting this form, I understand that Noom will process my personal information in accordance with their Privacy Policy.

Related Content

  • Blog
  • Obesity care and GLP-1s
  • May 1
  • 1 min read

Employer Strategies for Maximizing the Promise of GLP-1s

The numbers are clear: 160 million adults in the U.S. want to improve their health and well-being through weight loss. As many employers already know, adding obesity management programs to health benefit plans can boost employee motivation and health outcomes. For those who are affected, reducing weight by just 5-10% can improve risk factors and […]

By Noom Team
  • Blog
  • Obesity care and GLP-1s
  • September 5
  • 1 min read

From Weight Loss to Risk: Understanding GLP-1’s Impact on Eating Disorders

Weight loss medication abuse is not new. Diet pills, caffeine, laxatives, and others have been around for a long time, but with the emergence of GLP-1s, more reports of disordered eating have surfaced. While these drugs have helped millions of individuals reach their weight loss goals, many suffer side effects that ultimately lead them to discontinue use, resulting not only in money lost, but weight regain. In this post, we'll deep dive into the discussion around GLP-1s and eating disorders, to ensure that employers, providers and health plans have access to the right support for members on GLP-1s.

By Jennifer Jones
  • Webinar
  • Obesity care and GLP-1s
  • May 10
  • 1 min read

Bridging the GLP-1 Care Gap for Better Outcomes and ROI

While GLP-1 medications have shown much promise for weight loss, they can leave people in worse health than before, especially when medications are not used according to the drug label: as an adjunct to a diet and exercise program.  Yet, our healthcare system isn’t well-equipped to support patients during and after a GLP-1 course of […]

By Noom Team

Bring Noom to
your organization

Give your workforce a preview of what’s possible
for their physical and mental health.

REQUEST DEMO